Product Description
Mechanisms of Action: cGAS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant,Intramuscular,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vitaflo International
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624000125527 | P1 |
Recruiting |
Arthritis, Rheumatoid |
2024-09-02 |